Tim­ber Phar­ma­ceu­ti­cal­s' can­di­date for rare skin dis­or­der flunks all end­points in late-stage tri­al

Der­ma­tol­ogy biotech Tim­ber Phar­ma­ceu­ti­cals’ Phase 3 tri­al in­ves­ti­gat­ing its treat­ment in a rare in­her­it­ed skin dis­or­der missed all pri­ma­ry and sec­ondary end­points, the com­pa­ny an­nounced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER